Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-term, Open-label Extension Study of the Safety and Tolerability of RGH-188 (Cariprazine) in Patients With Schizophrenia

Next Previous
Trial Profile

A Long-term, Open-label Extension Study of the Safety and Tolerability of RGH-188 (Cariprazine) in Patients With Schizophrenia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories

    • Most Recent Events

    • 30 Jun 2021 Results of post -hoc analysis from NCT00404573, NCT01104779, NCT00694707, NCT01104766, NCT01104792, NCT00839852, NCT01412060, EudraCT 2012-005485-36 assessing safety Profile of Cariprazine and Potential Relevance for Patient Adherence in Schizophrenia presented at the 15th World Congress of Biological Psychiatry
    • 09 May 2018 Results of post-hoc analysis (n=112) assessing the efficacy of cariprazine on negative symptoms after up to 1 year of treatment using pooled data from 2 open-label, 48- week studies (NCT01104792, NCT00839852) along with supportive analysis results using data from the open-label run- in (8 week) and stabilization (12 week) phases of a long-term, cariprazine relapse-prevention study (NCT01412060), presented at the 171st Annual Meeting of the American Psychiatric Association.
    • 25 Nov 2014 New source identified and integrated (Clinical Trials Registry - India record, CTRI2009-091-000395).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top